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Changes in recipient and donor characteristics are redeﬁning the role of induction in liver transplant recipients.
Older recipients are more common, with greater concomitant comorbidity. Moderate or severe renal dysfunction
is now estimated to affect 40% of liver transplant recipients. Donors are also becoming older, and other factors
such as more frequent non-alcoholic fatty liver disease (NAFLD) compromise the quality of some grafts. Rejection
rates are now relatively low (~10%) but some patients have a markedly increased risk such as younger recipients
and those undergoing re-transplantation. Induction immunosuppression is associated with a signiﬁcant reduction
in rejection risk but due to various factors universal induction is not justiﬁed. Steroid-free therapywithout induction
increases the risk of biopsy-proven acute rejection (BPAR) but randomized trials have shown that inductionwith an
interleukin-2 antagonist receptor (IL-2RA) agent or with rabbit antithymocyte globulin (rATG)maintains immuno-
suppressive efﬁcacy in steroid-free regimens. Delayed calcineurin inhibitor (CNI) initiation (e.g. to days 4−5 post-
transplant) can prevent deterioration of renal function during the ﬁrst year post-transplant, but requires induction
with an IL-2RA agent or rATG tomaintain early immunosuppressive efﬁcacy. IL-2RA inductionmaybe inadequate to
ensure a low risk of rejection in a steroid-free regimen combinedwith delayed tacrolimus. Randomized trials of CNI
withdrawal at month 1 post-transplant have only achieved an acceptable rate of BPAR when induction is adminis-
tered. In terms of safety, an increased rate of infection does not seem to be a concern. The most recent large-scale
analyses havenot indicated any evidence for an increased risk ofmalignancy, or speciﬁcally post-transplant lympho-
proliferative disease. In summary, the place of induction in themanagement of liver transplant patients is becoming
established. Selective use in high-risk individuals to avoid graft rejection is still relevant, but the key rationale for
induction is to facilitate steroid-sparing and CNI-sparing regimens to reduce long-term complications.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The ﬁeld of liver transplantation is changing rapidly. The number of
transplants is growing annually [1], partly due to factors such as wider
acceptance of expanded criteria donors (ECD) and developments in
machine perfusion that are expanding the donor pool. At the same
time the proﬁle of recipients is changing due to alterations in population
demographics and in selection criteria. In parallel, acute cellular
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rejection rates have fallen to little more than 10% [2], with higher
recipient and donor age likely making a contribution [2,3]. Long-term
graft survival rates have improved, with 10-year survival rates in the
US now reaching 60% [2], although the increase in one-year survival
appears to be plateauing [2]. In contrast, patient survival rates have
not changed substantially in recent years [2], reﬂecting the growing
proportion of older donors with more comorbidities [4].
These changes are mirrored in new priorities for immunosuppres-
sion that take into account the risk proﬁles, clinical status and
comorbidities of recipients. The proportion of liver transplant patients
given induction immunosuppression increased markedly after the
introduction of graft allocation according to Model of End-Stage Liver
Disease (MELD) and Pediatric End-Stage Liver Disease (PELD) scoring
[5], and is now given to more than 30% of all adults and children [2].
One important contributing factor is that MELD-based allocation favors
transplantation of patients with renal impairment, and renal-sparing
regimens typically include induction (see ‘Renal dysfunction and
calcineurin inhibitor therapy: a remit for induction’). Currently,
interleukin-2 receptor antagonist (IL-2RA) induction is slightly more
frequently used than T-cell depleting therapy for both adults and
children undergoing liver transplantation [2].
Rational prescribing of induction demands an understanding of the
evidence supporting its use in speciﬁc settings. This review considers
the role of induction against the background of changing scenarios
and priorities in liver transplantation. It focuses on the two agents
used most widely in this context: rabbit antithymocyte globulin
(rATG, Thymoglobulin®) and the IL-2RA agent basiliximab
(Simulect®).
2. Evolution of donor and recipient characteristics
2.1. Donors
The average age of liver transplant donors is increasing, with more
than 30% of donors in Europe now aged 60 years or older [6]. Indeed,
an upper donor age limit for liver transplantation has recently been
withdrawn in several countries. In addition to older age, donor quality
is compromised by high body mass index (BMI) and the presence of
diabetes [7], both of which are becoming more common in developed
countries. The prevalence of non-alcoholic fatty liver disease (NAFLD)
is rising, with one study from Italy reporting NAFLD in over 30% of
donors [8]. NAFLD in the donor adversely affects graft and recipient
outcomes [9] and is likely to lead to a higher rate of rejected donor livers
in the future as the prevalence continues to rise. One large single-center
study assessed the proportion of higher-risk grafts among 1152 liver
transplants performed during 2000 to 2011, deﬁning ‘higher risk’ as
donation after cardiac death (DCD), donor age N60 years, donor body
BMI N30 kg/m2, donor intensive care stay N7 days, or donor serum
sodium N165 mmol/L and/or donor serum bilirubin N51 μmol/L [10].
The prevalence increased from 31.8% in 2000−2003 to 40.9% in 2004
−2007 and 59.1% in 2008−2011 (p b 0.001).
Advances in the ﬁeld ofmachine liver perfusion,with use of dynamic
preservation technology may help to improve the performance of
marginal graftswith extensive steatosis or fromolder donors to increase
rates of immediate graft function and also allow viability assessments
before acceptance [11]. Improving the viability of higher-risk grafts
may also lead to expanded use of DCD donation [12]. Importantly,
machine perfusion can also help identify which marginal grafts do not
merit transplantation, avoiding failed transplants.
2.2. Recipients
Older recipients (≥65 years) now account for more than 20% of
procedures in the US [2], which aswell as increasing levels of comorbid-
ity is inﬂuencing the pattern indications for liver transplant.
Among wait-listed patients, chronic liver failure due to non-
alcoholic steatohepatitis (NASH) and alcoholic liver disease, and hepa-
tocellular carcinoma (HCC) related to hepatitis C virus (HCV) infection,
are growing in frequency [13,14]. There has been a pronounced decline
in HCV-related ﬁbrosis as a cause for wait-listing and liver transplanta-
tion in the era of direct acting antiviral (DAA) therapy. Indeed, NASH is
now the secondmost frequent cause of end-stage liver disease [15], and
is likely to become the leading cause shortly as virus-related disease
declines. Malignancy, including HCC related to HCV infection or NASH,
is also a growing cause of liver transplantation, with a tripling in the
number of patients transplanted for malignancy in the last 10 years [2].
Related to these changes and also toMELD-based allocation of donor
grafts, medical urgency is increasing, with approximately 20% of US
recipients now having decompensated disease at the time of transplant
[2]. Patients with acute-on-chronic liver disease, which has extremely
high mortality on the waiting list [2], still represent a small proportion
of liver transplant recipients due to problems with identiﬁcation, refer-
ral, organ availability and timingof transplantation [16] but evidence for
good outcomes after transplantation [17] may promote further efforts
to increase transplantation of this critically ill group [18]. Additionally,
the priority given to patients with impaired renal function means that
combined liver-kidney transplants now account for almost 10% of liver
transplants in the US [2], further increasing the complexity of cases.
3. Risk of rejection after liver transplantation
Inclusion of induction in the immunosuppressive regimen following
liver transplantation is by no means required in all cases. When a
conventional regimen of calcineurin inhibitor (CNI) and steroids is
given from time of transplant, possibly also with mycophenolic acid
(MPA), the risk of rejection – be it T-cell mediated or humoral – should
be taken into account.
3.1. Recipient and donor risk factors for rejection
Younger recipient age is awell-recognized risk factor for risk of acute
cellular rejection [19,20]. Compared to patients aged 40 years, those
aged 18–25 years have a three-fold increase in risk while patients
aged ≥65 years have only ~70% of the risk [19]. Infants, however, have
a lower risk for rejection than older children [21]. African-American
race increases the risk for liver allograft rejection signiﬁcantly [15,20].
The indication for liver transplantation may also play a role, with the
available data suggesting that primary sclerosing cholangitis (PSC)
[19,20,22] and autoimmune hepatitis (AIH) [23,24] are associated
with a greater risk for acute rejection than other indications. Patients
undergoing re-transplantation are more likely to experience acute
rejection [19] here partly due to more frequent development of de
novo donor-speciﬁc antibodies (dnDSA) [25].
There is no convincing evidence that the relative risk of acute
rejection varies to any relevant degree in recipients of a living-donor
graft compared to a deceased-donor graft [24], or a living-related versus
living-unrelated graft [26]. Studies relating to the effect of combined
liver-kidney transplantation are scarce, but no increase in rejection
risk versus liver-only transplants has been shown to date [27,28].
3.2. Immunological risk factors for rejection
Positive T-cell cross-match, which occurs in approximately 7% of
liver transplant procedures [29], shows a clear association with
increased risk for acute rejection and lower ﬁve-year graft survival
[23,30–33]. One recent study observed a four-fold increase of risk of
acute rejection among recipients with a positive cross-match in a series
of 413 living-donor recipients, and more frequent preservation injury
[23]. Induction therapy might be clinically relevant for these patients,
but T-cell cross-matching is not routinely checked in most liver
transplant centers. Further studies on its role are needed.
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The extent of HLA mismatching is a clear risk factor [23,30,34]. One
meta-analysis of four studies found the risk ratio for acute rejection to
be 0.77 in patients with 0–2 mismatches compared to a reference
group of patients with 3–6 mismatches [34]. Shindoh et al. found HLA-
DR mismatch, speciﬁcally, to be an independent risk factor for acute
cellular rejection (odds ratio [OR] 2.99; p = 0.013) after living-donor
liver transplantation [23]. However, the ubiquity of HLA mismatching
in liver transplantation [35] means that decision-making about induc-
tion is not generally inﬂuenced by the number of HLA mismatches.
Awareness of the impact of DSA in liver transplantation is growing,
with recent studies in adult patients estimating the incidence of
preformed and dnDSA to be 13–15% [25,36] and 8–9% [36–38], respec-
tively. Rates are higher in children [39]. Although data are limited,
liver transplant recipients with preformed or dnDSA appear to be at in-
creased risk for antibody-mediated rejection (AMR) [25,40,41] com-
pared to DSA-negative individuals. The liver may be relatively
resistant to AMR, however, due to its large size and sinusoidal
microvascular bed, secretion of high levels of soluble HLA and
phagocytosis by Kupffer cells in the liver, and the organ's regenerative
capacity in response to injury [42]. More evidence is awaited on the
implications of DSA, and particular DSA classes, in liver transplant
patients before DSA monitoring is routinely performed in this setting.
4. Other factors affecting induction decision-making
In recent years, clinician decision-making processes in immunosup-
pression have been increasingly guided by the need to minimize early-
and long-term CNI-related adverse events. Induction plays a pivotal role
in supporting both steroid-sparing and CNI-sparing regimens after liver
transplantation, as discussed below. Certain types of patient are likely to
gain particular beneﬁts from such regimens.
Older age, as expected, negatively impacts survival rates [1,43,44],
partly due to an increased risk of infectious death [20,45]. Post-
transplant infections are also more frequent in patients with higher
MELD scores [45,46]. For older or critically ill individuals with an
increased risk for infection early after transplantation, minimization of
immunosuppression is paramount and could be facilitated by induction.
Malignancy prior to transplantation [47] and transplantation with
malignancy as the primary indication [1,48] are associated with a
relevant increase in tumor-related mortality and CNI minimization
can be prudent in this setting. Where recipients are at increased risk
of infection or malignancy, use of induction to support rapid tapering
or withdrawal of CNI therapy to achieve a low-intensity maintenance
regimen may be beneﬁcial.
5. Induction and outcomes: ﬁndings from large-scale analyses
A small number of registry analyses and meta-analyses have evalu-
ated outcomes according to whether induction was administered, and
the type of agent used [5,49,50]. Data, however, are typically based on
populations transplanted no later than the 2000s.
Regarding risk for acute rejection, a Cochrane analysis found that in-
duction of any type was associated with a clear beneﬁt when analyzed
across 1918 liver transplant patients in 16 randomized clinical trials, cal-
culating a relative risk of 0.85 (95% conﬁdence interval [CI] 0.75; 0.96)
versus no induction [50]. Ameta-analysis which included only pediatric
liver transplant recipients (n = 431) also found a signiﬁcant reduction
in acute rejection in patients given induction versus controls [51].
Evidence concerning graft and patient survival is more complex
since so many factors contribute. In a registry analysis of over 60,000
patients transplanted up to 2008, Moonka et al. observed signiﬁcantly
higher graft survival up to ﬁve years post-transplant (69.5% versus
66.2%, p b 0.001) in the subgroup given induction of any type versus
thosewithout induction [5]. Five-year patient survivalwas also superior
(74.8% versus 72.4%, p b 0.001). The differences in survival rates
emerged by year 1 and remained stable thereafter, supporting an early
beneﬁcial effect of induction (Fig. 1). Although the positive impact of
induction remained persistent on multivariate analysis, a residual
selection bias cannot be ruled out in such analyses. A Cochrane analysis
of 19 randomized trials which compared any induction versus no
induction has also been carried out, but inevitably involved far fewer
patients (n = 2067) with shorter follow-up [50]. In that analysis,
there was no signiﬁcant effect of induction on either graft or patient
survival although there was a trend to improved graft survival [50]. In
US registry analyses comparing graft and patient survival according to
whether patients received rATG/ATG or IL-2RA induction [5,49], there
was a strong trend towards superior outcomes with rATG/ATG versus
IL-2RA therapy. However, numbers were relatively low and no ﬁrm
conclusions can be drawn.
6. Steroid-free immunosuppression: the role of induction
Peri-operative intravenous steroids are universally prescribed for
liver transplantation to ameliorate ischemia-reperfusion injury (IRI)
[52], block innate and adaptive immunity and enhance regulatory
T-cell activity [53]. For post-operative oral steroid therapy, however,
protocols and dose levels vary widely. While steroid withdrawal at
various time points during the ﬁrst year post-transplant is common
[54], ‘steroid-free’ therapy – i.e. no oral steroid therapy – remains
uncommon after liver transplant procedures [54].
A meta-analysis of randomized trials in liver transplant populations
found no signiﬁcant difference in graft or patient survival for steroid-
free versus standard steroid regimens, but rates of cytomegalovirus
(CMV) infection and mean cholesterol levels were signiﬁcantly lower
with steroid-free therapy, and there was a trend to less frequent
hypertension [55]. Evidence concerning an effect on recurrence of HCC
is mixed [56,57]. Potential long-term effects, such as limiting the risks
for post-transplant diabetes, may be the most pressing reasons for
seeking steroid-free therapy. Steroid-free regimens are not advisable
in patients with autoimmune disorders such as PSC or AIH which
require maintenance steroid therapy.
Where steroid-free therapy is planned, induction with rATG or an
IL-2RA agent is generally adopted to maintain immunosuppressive
potency. In a meta-analysis of 10 randomized trials published up to
2007, Segev et al. found that the relative risk of biopsy-proven acute
rejection (BPAR) was increased by 31% when no induction was given
in steroid-free regimens, but was reduced by 32% versus standard
steroid therapy when induction (or mycophenolate mofetil [MMF])
was added [55].
6.1. IL-2RA induction
A randomized trial of steroid-free therapy in 602 deceased-donor
liver transplant patients showed that IL-2RA inductionwith daclizumab
achieved a similar level of BPAR to ongoing MMF therapy when either
was given with tacrolimus (19.7% versus 16.2%) [58]. Drug-related
adverse events and bacterial infections were, as would be expected,
more frequent in the MMF group. In that trial, tacrolimus levels were
relatively high compared to today's practice (10–20 ng/mL to week 6,
then b10 ng/mL thereafter). Using lower tacrolimus exposure (mean
9 ng/mL to month 6), another randomized trial in 157 patients found
that a steroid-free combination of daclizumabwithMMFand tacrolimus
achieved a lower rate of BPAR than standard tacrolimus/steroid therapy
(11.5% versus 26.6%, p b 0.05) [59]. The efﬁcacy of daclizumabwith both
MMF and tacrolimus in a steroid-free regimen (targeting tacrolimus
9–11 ng/mL) was again shown to lower the rate of BPAR versus
tacrolimus/steroids, and also versus tacrolimus/MMF/steroids in a
randomized trial of 312 patients published by Klintmalm et al. in 2005
[60]. A similar observation was reported in the recent randomized
DIAMOND study of 844 liver transplant patients, where basiliximab
induction with tacrolimus and MMF was associated with 12.1% BPAR
at one year compared to 17.9% for tacrolimus and MMF, both in a
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steroid-free regimen (p = 0.016) (Fig. 2) [61]. The results from the
DIAMOND study are relevant today since tacrolimus exposure
(b10 ng/mL from week 2 onwards) is comparable to current practice.
Results from the DIAMOND study showed that delaying tacrolimus
until day 5 was associated with 16.8% BPAR compared to 12.1% with
immediate tacrolimus, a difference that was statistically signiﬁcant
(p = 0.039) but of minor clinical relevance (Fig. 2) [61].
6.2. rATG induction
A randomized trial of steroid-free therapy using rATG induction
(1.5mg/kg on days 0 and 1)with tacrolimus andMMF showed a similar
rate of BPAR versus tacrolimus,MMF and oral steroids (25% versus 31%),
but fewer patients required pulsed steroids in the rATG/steroid-free
cohort (6.6% versus 50.0%, p = 0.03) [62]. As in many of the
steroid-free trials using IL-2RA induction, tacrolimus exposure was
higher than currently (10–12 ng/mL to month 3). One retrospective
analysis of prospectively collected data, published in 2015, assessed
rATG with delayed tacrolimus at more modern exposure levels
(6–8 ng/mL), MMF and no oral steroids [63]. At a mean follow-up of
43 months, 22.8% patients had experienced BPAR, with pulsed steroids
required in 6.6% [63]. Delayed tacrolimus in a steroid-free regimen
appears feasible with rATG and MMF therapy.
Only one study, of a retrospective design, has compared rATG versus
basiliximab in liver transplant patients managed with steroid-free
therapy [64]. rATG was the induction agent of choice (n = 322), with
basiliximab given in cases of persistent post-operative hemodynamic
instability, persistent cardiac arrhythmias or pulmonary hypertension
(n = 273). All patients were given tacrolimus starting from day 4
(10–12 ng/mL to month 3, then 3–5 ng/mL) with MMF given only to
patients with renal dysfunction to support low-exposure tacrolimus
[64]. BPAR was less frequent at ﬁnal follow-up in the rATG group (18%
versus 27%) with a reduced risk for graft loss, but selection bias limits
interpretation. However, it seems reasonable to conclude that rATG
induction enables steroid-free therapy with tacrolimus and MMF after
liver transplantation, and may permit delayed tacrolimus initiation in
this context.
7. Renal dysfunction and calcineurin inhibitor therapy: a remit for
induction
7.1. Prevalence and risk factors for renal dysfunction
Liver cirrhosis can induce renal dysfunction via renal hypoperfusion,
with the risk for acute tubular necrosis if left untreated, compounded by
hepatorenal syndrome in advanced liver disease [65,66]. Introduction of
MELD-based allocation criteria inevitably led to an increase in renal
dysfunction among liver transplant recipients [67], with one US study
reporting moderate or severe chronic kidney disease (chronic kidney
disease [CKD] stage ≥3) in 40% of cases [68]. Hepatorenal syndrome
resolves after transplantation, but progressive post-transplant
deterioration of renal function is widespread. End-stage renal disease
affects up to 10–20% of patients by ﬁve years post-transplant [69,70],
increasing the risk of hospitalization two-fold [71] and the risk of
death by as much as three-fold [72].
The risk of renal dysfunction after liver transplantation is closely
associated with pre-transplant renal status [68,73]. Conventional risk
factors for renal deterioration also apply, notably diabetes [68,72] and
older age [72]. One of the few modiﬁable variables is chronic
CNI-related nephrotoxicity with its hallmark signs of arteriolar
hyalinosis, interstitial ﬁbrosis and glomerular sclerosis [74]. Even in
the era of low-dose tacrolimus, long-term CNI-related distortions to
renal architecture are common [75]. Since almost all patients receive
CNI therapy after liver transplantation, few studies have been able to
assess the clinical impact. In the ICEBERG study, a multicenter
retrospective analysis of 402 adult liver transplant patients who
survived for at least two years after transplantation, 368 patients were
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Fig. 1. Observed graft and patient survival in primary liver transplant recipients enrolled with the United Network of Organ Sharing (OPTN) database up to 2008, according to whether
induction of any type was given or not [5].
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Fig. 2. Mean tacrolimus trough concentration and clinical outcomes at month 6
post-transplant in the randomized DIAMOND trial of 844 primary liver transplant
recipients [61]. All patients received prolonged-release tacrolimus (5−15 ng/mL to
week 7 and 5−12 ng/mL thereafter) with MMF (2 g/day to week 2 and 1 g/day
thereafter) and were randomized to (i) no additional therapy (ii) basiliximab induction
or (iii) basiliximab with delayed introduction of tacrolimus until day 5. BAS, basiliximab;
BPAR, biopsy-proven acute rejection; eGFR, estimated GFR; MMF, mycophenolate
mofetil; TAC, tacrolimus
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givenCNI therapy (155 cyclosporine, 149 tacrolimus) and 64wereman-
aged with CNI-free regimens [76]. On multivariate analysis, the risk of
chronic renal dysfunction was more than two-fold higher in CNI-
treated patients (hazard ratio [HR] 2.31; 95% CI 1.05, 5.07; p = 0.037).
The effect is dose-dependent. A study of 57 pediatric liver transplants
found that the cyclosporine trough concentration was a signiﬁcant
time-dependent predictor for development of CKD (stage ≥3) [77].
High CNI exposure has also been shown to increase the risk of acute
renal injury after liver transplantation by more than two-fold [78].
7.2. Induction to facilitate CNI minimization
A key role for induction therapy after liver transplantation is to
facilitate CNI sparing. Recipients at high risk for post-transplant CKD
are clear candidates for CNI-sparing regimens. In fact, it could be argued
that CNI minimization should be applied broadly in an attempt to
preserve long-term renal function after liver transplantation. Various
CNI minimization regimens have been explored to help preserve
long-term renal function after liver transplantation, the majority of
which have included induction.
7.2.1. Delayed CNI initiation
Several studies published in 2005–2010 investigated use of delayed
CNI initiation, to reduce the early renal insult immediately
post-transplant [79–83]. Calmus et al. undertook a two-year random-
ized trial of tacrolimus, MMF and oral steroids in which 199 primary
liver transplants with acceptable renal function (serum creatinine
≤180 μmol/L) were randomized to tacrolimus started on day 1 without
induction, or on day 5 with daclizumab induction [79]. Performed dur-
ing the early 2000s, the study used a tacrolimus target level of
10–20 ng/mL to week 5 then 5–15 ng/mL. Rates of BPAR were similar
between groups, but despite a trend to improved renal function
(eGFR) at month 6 in the delayed tacrolimus/daclizumab group eGFR
was comparable by month 12 [79]. In a similar population, Yoshida
et al. also randomized patients to immediate or delayed (day 4) tacroli-
mus with daclizumab, both withMMF and steroids, but this time tacro-
limus exposure was also lower in the delayed-initiation group during
month 1 [81]. BPAR rates were similar between groups, but despite an
early renal beneﬁt from delayed/reduced tacrolimus was again lost by
month 6. A longer-term renal beneﬁt was achieved by Neuberger et al.
in a cohort of 517 primary liver transplant patients with serum creati-
nine ≤200 μmol/L at time of transplant [80]. In this three-arm study, pa-
tients were given tacrolimus (N10 ng/mL to month 1) with steroids,
tacrolimus (≤8 ng/mL) with MMF and steroids, or tacrolimus from day
5 (≤8 ng/mL) with daclizumab induction and steroids. The
daclizumab-treated group had the lowest tacrolimus exposure until
month 3, with signiﬁcantly better preservation of renal function at
year 1, and signiﬁcantly less frequent early treated BPAR (Fig. 3). As
described above, when basiliximab was used to support steroid-free
therapy with delayed tacrolimus in the DIAMOND study, there was
only a minor difference in the incidence of BPAR compared to
immediate tacrolimus (Fig. 2) [61]. To summarize, IL-2RA induction
with delayed tacrolimus does not compromise immunosuppressive
efﬁcacy and can improve early renal function.
Two large retrospective studies have compared outcomes using
rATG with delayed tacrolimus versus control groups given tacrolimus
immediately post-transplant [82,83]. In both studies, oral steroids
were given at least to month 3 [82,83]; one included low-dose MMF
(1 g/day) to month 6 [82]. The two studies showed that rATG with
delayed tacrolimus initiation signiﬁcantly reduced the rate of BPAR at
one year versus standard therapy – and renal function was signiﬁcantly
better at 1 year [82,83]. Interestingly, a large-scale Organ Procurement
and Transplantation Network (OPTN) analysis of 1720 liver transplant
patients performed up to 2005 found that use of rATG versus no
induction was associated with a 2.2-fold increase in recovery of renal
function after liver transplantation in patients with pre-transplant
CKD (p = 0.022), possibly related to delayed CNI exposure [84].
Although randomized trials are lacking, these ﬁndings are encouraging.
7.2.2. Reduced CNI exposure
One randomized trial, published by Boudjema et al. in 2011,
compared reduced-exposure tacrolimus started immediately after
transplantation with concurrent MMF and steroids versus standard-
exposure tacrolimus and steroids [85]. No induction was given. The
rate of clinically-suspected acute rejection was 30% in the reduced-
tacrolimus/MMF group versus 46% in controls, but without biopsy con-
ﬁrmation it is difﬁcult to assess the efﬁcacy of the investigational arm. A
renal beneﬁt was seen in the reduced-tacrolimus group [85]. Use of a
mammalian target of rapamycin (mTOR) inhibitor also appears effective
supporting reduced CNI exposure without the need for induction. The
randomized H2304 study demonstrated that an early switch
(at month 1) to reduced-exposure CNI with the mTOR inhibitor
everolimus, plus steroids, appears feasible without induction [86]
while retrospective data have indicated that de novo everolimus with
reduced-exposure tacrolimus from the day of transplant can also offer
adequate immunosuppressive potency [87,88]. Both approaches
improved renal outcomes without requiring induction [86,87].
7.2.3. CNI withdrawal
Randomized trials have assessed the effect of early CNI withdrawal
(~1 month post-transplant), with introduction of an mTOR inhibitor
[86,89–91]. The two randomized trials which included induction (both
using basiliximab) showed no increase in BPAR after CNI discontinua-
tion [89,90]. In marked contrast, in the H2304 study where no patient
received induction, recruitment to the tacrolimus withdrawal arm was
discontinued due to excess BPAR [86]. Similarly, in the Spare The
Nephron study where only 29.4% of patients received induction, BPAR
was signiﬁcantly higher after tacrolimus withdrawal [91]. The evidence
seems clear-cut that without induction, the risk of BPAR increases sig-
niﬁcantly with early switch from CNI to mTOR inhibitor therapy and in-
duction therapy is prudent (Table 1).
Reviewing the available evidence, renal function during theﬁrst year
post-transplant may be optimized by delaying CNI therapy until day 4
or 5, potentially with steroid-free therapy or early steroid withdrawal,
but induction is necessary to protect against rejection. Where CNI ther-
apy is to bewithdrawn, for example aroundmonth 1, induction also ap-
pears favorable. Reduced-exposure CNI with adjunctive use of MPA or
Time post-transplant (months)
1 2 3 4–6 7–10 10–12
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TAC/steroids
TAC/MMF/steroids
Delayed TAC/DAC/steroids
Treatment group tBPAR at P value Change in eGFR P value
 M6 (%)  (BL to M12)
TAC/steroids 23.2  –23.6 
TAC/MMF/steroids 25.0 <0.05 –21,2 0.012
Delayed TAC/DAC/steroids 14.9  –13.6 
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Fig. 3.Mean tacrolimus trough concentration and clinical outcomes in a randomized trial
of 517 primary liver transplant recipients [80]. Patients received (i) tacrolimus (N10ng/mL
to month 1 then according to local practice) with oral steroids (ii) tacrolimus ≤8 ng/mL
with MMF (dosed at 2 g/day to week 1) and steroids or (iii) tacrolimus ≤8 ng/mL with
daclizumab induction and oral steroids. BL, baseline; DAC, daclizumab; eGFR, estimated
GFR (mL/min/1.73 m2); M6, month 6; M12, month 12; MMF, mycophenolate mofetil;
TAC, tacrolimus; tBPAR, treated biopsy-proven acute rejection
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anmTOR inhibitor, with steroids, may not require induction tomaintain
efﬁcacy. However, if any early CNI minimization approach is planned
with a steroid-free regimen, induction should be given.
8. Ischemia-reperfusion injury: a role for rATG?
The question of whether intraoperative rATG administration can
ameliorate IRI is intriguing. Interest was triggered by a randomized
trial of kidney transplant patients byGoggins et al., which demonstrated
that intraoperative rATG reduced the rate of delayed graft function and
improved early graft function [92]. A randomized single-center trial in
22 liver transplant patients has compared no induction versus rATG,
given as three 1.5 mg/kg doses (one administered anhepatically at the
start of the transplant procedure, and then on days 2 and 4) [93]. Clini-
cally there was less evidence of IRI in the rATG group, with signiﬁcantly
lower mean alanine transaminase (ALT) levels on day 2. Data from a
non-humanprimatemodel has suggested that rATGmay exert a protec-
tive effect by reducing leukocyte adhesion via down-regulation of leu-
kocyte chemokine receptors and reducing inﬂammation and tissue
damage in reperfused tissues [94,95]. In vitro evidence has shown that
rATG inhibits leukocyte migration to chemotactic signals [96]. A retro-
spective analysis of recipients of DCD liver grafts has also indicated
that rATGmay offer a protective effect on the biliary epithelium, reduc-
ing ischemic stricture formation for grafts transplanted from DCDs [97].
Any effect of rATG on IRIwould require intraoperative, anhepatic ad-
ministration. As a note of caution, a non-randomized case study which
assessed the use of a high single intraoperative dose of rATG
(3 mg/kg) in 16 liver transplant patients found evidence of cytokine
syndrome and other side effects [98]. A lower intraoperative dose
(e.g. 1.5 mg/kg) would be advisable.
9. Safety issues in liver transplantation
Two main safety issues are of potential concern in relation to induc-
tion: the risk for infection and risk for post-transplant malignancies.
A Cochrane analysis published in 2014which included 1424 patients
from 11 randomized trials of induction (of any type) versus no
induction found no effect of induction on risk of infections overall
(relative risk 0.90 [95% CI 0.76; 1.06]) [50]. The same analysis, based
on 1543 patients in 10 randomized trials, showed no difference in risk
of CMV infection (relative risk 1.24 [95% CI 0.93; 1.67]) [50]. There
was no increase in infections or CMV infections when IL-2RA induction
and rATG induction were considered separately, although patient
numbers were low for rATG (n = 115) [50]. Individual studies of
IL-2RA induction [79–81] or rATG [82,83] with delayed CNI initiation
have reported no effect on infection rates with either category of
induction. Infections do not seem to be a concern when considering
use of induction after liver transplantation.
Concern about the risk of non-Hodgkin’s lymphoma (NHL) in
patients given lymphocyte-depleting induction arose following a
Collaborative Transplant Study of kidney transplants, spanning the
period 1985–2004 [99]. However, a more recent analysis from the
same group, involving 38,311 kidney transplants from 2004–2013,
found no increase in risk of NHL compared to no induction [100],
likely reﬂecting exclusion of older lymphocyte-depleting agents
(e.g. OKT3) and lower doses of ATG. The relative rarity of NHL, and
more generally post-transplant lymphoproliferative disease
(PTLD), means that randomized trials are too small to provide mean-
ingful data, but a Cochrane analysis of induction generally found no
increase in malignancy overall or PTLD associated with induction
after liver transplantation (Table 2) [50]. When the analysis was re-
peated speciﬁcally for studies of IL-2RA induction or rATG, no in-
crease in malignancy or in PTLD was seen with either type of
induction (Table 2). Thus, although accurate assessment of malig-
nancy rates is challenging, there is no evidence for an induction-
related increase in risk. Based on modern dosing, levels of rATG
(e.g. a cumulative dose of no more than 7.5 mg/kg, and frequently
lower, over a maximum of ﬁve days) do not appear to inﬂuence the
risk of post-transplant PTLD or malignancy.
Evidence relating to recurrence of HCV in patients given induction
versus no induction, while limited, has not suggested an effect [50].
Any studies that have found a signiﬁcant difference in fact showed a
lower risk for recurrence under rATG versus no induction [101] or
versus no induction/basiliximab [102], possibly through a CNI-sparing
effect. In light of the recent introduction of DAA, however, the topic is
of less interest.
There are almost no valid data comparing HCC recurrence with or
without induction [103].
Table 1
Summary of rejection risk in randomized controlled trials of reduced-exposure CNI or early CNI withdrawal in liver transplantation.
Study Population (all adults) n Induction CNI minimization group Control group BPAR after RND P value
Reduced CNI exposure
H2304 [86] Primary tx deceased
donor eGFR ≥30
719 None Everolimus reduced TAC
steroids to ≥6 months
Standard TAC steroids
to ≥6 months
4.1% vs 10.7% 0.005
Boudjema 2011 [85] Primary tx deceased
donor SCr ≥130 μmol/L
195 None Reduced TAC
MMF steroids
Standard TAC steroids 30% vs 46% (not
biopsy-conﬁrmed)
0.024
CNI withdrawal
PROTECT [89] ≤70 years primary tx
acceptable renal
function
no rejection
203 BAS Day 30: switch from
TAC or CsA to EVR
(by month 4) ±Steroids
TAC or CsA ±Steroids 17.7% vs 15.3% n.s.
Masetti 2010 [90] Primary tx
deceased donor
CIT ≤12 h
78 BAS Day 10: switch from CsA
to EVR by day 30 steroids
to week 5
CsA steroids to week 5 5.7% vs 7.7% n.s.
H2304 [86] Primary tx deceased
donor eGFR ≥30
719 None Day 30: switch from TAC
to EVR (by month 4)
steroids to ≥6 months
TAC steroids to
≥6 months
19.9% vs 10.7% Recruitment to TAC
withdrawal arm
stopped
due to high BPAR
Spare the nephron
[91]
No steroid-resistant
rejection or ≥1 BPAR
eGFR ≥30
293 29.4% of
patientsa
Weeks 4–12: started
sirolimus,
TAC or CsA stopped
MMF ± steroids
TAC or CsA MMF ±
steroids
12.2% vs 4.1% 0.02
BAS, basiliximab; BPAR, biopsy-proven acute rejection; CIT, cold ischemia time; CNI, calcineurin inhibitor; CsA, cyclosporine; eGFR, estimatedGFR; EVR, everolimus;MMF,mycophenolate
mofetil; n.s., not signiﬁcant; RND, randomization; SCr, serum creatinine; TAC, tacrolimus; tx, transplantation
a rATG n = 36; IL-2RA n = 50
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10. Future perspectives
The place of induction in the management of liver transplant
patients is becoming established. With acute rejection now affecting
only one in ten liver transplant recipients, universal application of in-
duction therapy as an ‘add-on’ to standard therapy is not justiﬁed on
the grounds of lowering rejection rates. Exceptions apply, of course,
for example patients undergoing re-transplantation or those with a
positive T-cell cross-match, in whom addition of induction appears
advisable. The key rationale for induction in liver transplantation
protocols is to facilitate reduction or elimination of CNI therapy or
steroids in order to minimize long-term complications. In appropriate
patients, steroid-free therapy is a highly appealing option in order to
alleviate the burden of chronic steroid-related adverse events such as
diabetes, hypertension and osteopenia and induction is necessary to
ensure effective immunosuppression with steroid-free regimens in the
early post-transplant phase. Preservation of renal function, increasingly
recognized as a key clinical objective, may be assisted by delayed CNI
introduction and this demands effective induction to cover the interval
until adequate CNI blood concentrations are reached. Similarly, if early
CNI withdrawal is attempted induction is strongly advisable. Where
low-exposure CNI therapy is employed, induction seems less important
but potentially useful.
As the role of induction has clariﬁed, it has raised more questions to
answer. For example, what dosing regimen is appropriate for rATG in
critically ill patients – is reduced dosing sufﬁcient, or indeed beneﬁcial?
How do the immunological effects of rATG and IL-2RA induction differ
based on systematic immune monitoring, for instance in terms of
different types of regulatory cells? Undertaking randomized trials in
transplantation is now becoming challenging since conventional
endpoints such as acute rejection are less relevant, and the rapid
evolution of management practices means that the time required to
plan, perform and complete large studies often means that ﬁndings
are irrelevant at the point of completion. Frequently, adequate statistical
power cannot be achieved in this era of high success rates. Analyses of
international or large national transplant registries may help address
these problems, and further reﬁne our understanding of how best to
use induction in the context of liver transplantation.
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